Skip to content

News

Partner Member Profile: Ovarian Cancer Alliance of Greater ...

Partner Member Profile: Ovarian Cancer Alliance of Greater Cincinnati

The Ovarian Cancer Alliance of Greater Cincinnati (OCAGC) became a Partner Member of the Alliance in October 2010. “It’s been a very positive partnership,” says Martha Farr, an ovarian cancer survivor and co-chair of OCAGC’s Board of Trustees. The group started almost a decade ago, hosting an annual walk to raise awareness. Eventually, the volunteers … Continued

Decisions on a Knife-Edge: Risks and Benefits of Fallopian ...

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women.  Yet it’s not … Continued

Tailored Surgical Approach Leads to Better Outcomes in Ovar...

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program

Gynecologic Cancer Patients to Receive New Support in Baltimore, MD and Portland, OR WEST CHESTER, Pa (February 23, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC® today announced two new Woman to Woman grant recipients: Mercy Medical Center in Baltimore, MD, and Oregon Health and Science University in Portland, OR. The new sites are part … Continued

OCRF Research Finds New Therapeutic Strategy for Ovarian Ca...

OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer

(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued

New Tool Could Speed Development of Ovarian Cancer Drugs

New Tool Could Speed Development of Ovarian Cancer Drugs

(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued

Ovarian Cancer Research Fund Awards Nearly $6.5 Million in ...

Ovarian Cancer Research Fund Awards Nearly $6.5 Million in Grants

Total investment in the field now over $65 million New York, NY February 11, 2015 — To conclude Ovarian Cancer Research Fund’s 20th anniversary year, $6.453 million has been awarded in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. This brings OCRF’s total investment in research and related educational … Continued

Meet OCRF’s 2015 Grantees

Meet OCRF’s 2015 Grantees

(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational and support initiatives to nearly $70 million. The twenty new OCRF research grants have been awarded to top scientists at fourteen leading medical centers across … Continued

SGI-110 is an Ovarian Cancer Chemosensitizer

SGI-110 is an Ovarian Cancer Chemosensitizer

(February 4, 2014)  In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy.  The work was led by Dr. Kenneth Nephew, who was funded through an OCRF Program Project Development Grant. The development of resistance to chemotherapy in ovarian cancer … Continued

OCRF Research Identifies Six New Susceptibility Loci for Ov...

OCRF Research Identifies Six New Susceptibility Loci for Ovarian Cancer

(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer.  The findings were published this month in Nature Communications. Previous studies have identified 12 epithelial ovarian cancer susceptibility alleles (an allele is one of two or … Continued

Population Study Shows Salpingectomy Decreases Risk of Ovar...

Population Study Shows Salpingectomy Decreases Risk of Ovarian Cancer

(Feb. 2, 2015) Recent studies have suggested that ovarian cancer predominantly arises within the fallopian tubes or the uterus. A group of Swedish researchers hypothesized that surgical removal of the fallopian tubes (salpingectomy) is associated with a reduced risk for ovarian cancer. In the study, which involved hundreds of thousands of women, researchers compared women who … Continued

Partner Member Profile: Utah Ovarian Cancer Alliance

Partner Member Profile: Utah Ovarian Cancer Alliance

A year after her diagnosis with ovarian cancer in May 2011, Dr. Jan Byrne began looking for ways to be more involved in ovarian cancer advocacy and education. She connected with the Ovarian Cancer National Alliance and realized that there was a need for more services in Utah. “There wasn’t anything organized here for ovarian … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.